Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2008

Aerovance Closes $10M Financing Round

  • Aerovance secured $20 million in venture debt financing. Aerovance says that it drew down $10 million from the financing line at closing. The remaining $10 million is available upon the achievement of corporate milestones.

    The money will support development of Aerovant, which is in Phase IIa studies for asthma. Aerovant is a recombinant human IL-4 variant that is an inhibitor of both the IL-4 and IL-13 receptors.

    Oxford Finance Corporation led the syndicate, which includes Silicon Valley Bank and Comerica Bank.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »